ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last3,861 to 3,880 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
With Complications vs Without Complications: Factors Considered to Affect the Efficacy of Sertraline: Complication ;Complications is the Patient's Current Experiences With Illnesses, Operations, Injuries and Treatments.528 of 637

981 of 1,128

-4.1 points

-7.7 to -0.6

1,765NCT00605865

Drug Use Investigation of Jzoloft.

15 Years and Higher vs Under 15 Years: Factors Considered to Affect the Efficacy of Sertraline: 15 Years and Higher of Age or Not1,508 of 1,762

1 of 3

52.3 points

6.3 to 79.5

1,765NCT00605865

Drug Use Investigation of Jzoloft.

Task-shifted Epilepsy Care Arm (TSC) vs Enhanced Usual Epilepsy Care Arm (EUC): Number of Children for Whom an EEG Was Ordered6 of 879

22 of 885

-1.8 points

-3.1 to -0.6

1,764NCT04290975

Bridging the Childhood Epilepsy Treatment Gap in Africa

Task-shifted Epilepsy Care Arm (TSC) vs Enhanced Usual Epilepsy Care Arm (EUC): Diagnostic Accuracy846 of 879

826 of 885

2.9 points

0.8 to 5.0

1,764NCT04290975

Bridging the Childhood Epilepsy Treatment Gap in Africa

Early-ART vs Delayed-ART: serious adverse events526 of 886

522 of 877

-0.2 points

-4.7 to 4.4

1,763NCT00074581

Preventing Sexual Transmission of HIV With Anti-HIV Drugs

Vaccine vs Placebo: serious adverse events42 of 1,174

19 of 587

0.3 points

-1.6 to 2.0

1,761NCT01797029

A Randomized, Controlled Trial on the Efficacy and Safety of Live-Attenuated Influenza Vaccine (LAIV) Among Children in Bangladesh

Vaccine vs Placebo: serious adverse events7 of 1,174

7 of 587

-0.6 points

-1.9 to 0.3

1,761NCT01854632

Clinical Efficacy of Trivalent Live-Attenuated Influenza Vaccine (LAIV) Among Children in Senegal

Group ANC vs Stand ANC: deaths from any cause2 of 877

3 of 884

-0.1 points

-0.8 to 0.5

1,761NCT04033003

Group Antenatal Care and Delivery Project

Group ANC vs Stand ANC: serious adverse events2 of 877

3 of 884

-0.1 points

-0.8 to 0.5

1,761NCT04033003

Group Antenatal Care and Delivery Project

Email vs Post: Email vs Postal Recruitment: Number of GPs Completing the First Questionnaire138 of 880

132 of 880

0.7 points

-2.7 to 4.1

1,760NCT01206738

Developing and Evaluating Interventions to Reduce Inappropriate Prescribing of Antibiotics in Primary Care

Aliskiren Based Regimen vs Non-Aliskiren Based Regimen: Number of Participants With Composite Cardiovascular Endpoints in Aliskiren Based Regimen Versus Non-Aliskiren Based Regimen11 of 860

14 of 899

-0.3 points

-1.5 to 0.9

1,759NCT01259297

A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People

Aliskiren Based Regimen vs Non-Aliskiren Based Regimen: Number of Participants With Total Mortality in Aliskiren Based Regimen Versus Non-aliskiren Based Regimen5 of 860

9 of 899

-0.4 points

-1.4 to 0.5

1,759NCT01259297

A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People

Zoledronic Acid 4 mg Q4W vs Denosumab 120 mg Q4W: serious adverse events581 of 878

552 of 878

3.3 points

-1.2 to 7.8

1,756NCT00330759

Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.

Care Transitions Intervention vs Usual Care: Number of Participants Who Died Within 30 Days of Discharge2 of 863

5 of 893

-0.3 points

-1.1 to 0.4

1,756NCT02520661

Paramedic Coached ED Care Transitions to Help Older Adults Maintain Their Health

Nitazoxanide vs Placebo: serious adverse events4 of 872

1 of 884

0.3 points

-0.2 to 1.1

1,756NCT03605862

Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection

Everolimus vs Placebo: serious adverse events180 of 874

77 of 881

11.9 points

8.6 to 15.1

1,755NCT01674140

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

Etanercept vs nbDMARDs: serious adverse events77 of 211

534 of 1,543

1.9 points

-4.8 to 9.0

1,754NCT01557322

Characterize Patients With Moderately Active Rheumatoid Arthritis (RA)

qHPV Vaccine in Base Study vs Placebo in Base Study: Number of Participants Reporting Serious Adverse Experiences (SAEs) Through Month 186 of 1,165

0 of 584

0.5 points

-0.2 to 1.1

1,749NCT00092547

A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)

qHPV Vaccine in Base Study vs Placebo in Base Study: Number of Participants Reporting Other (Non-serious) AEs Through Month 18918 of 1,165

340 of 584

20.6 points

16.0 to 25.2

1,749NCT00092547

A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)

Arm 1: VAQTA™ vs Arm 2: VAQTA™ +ProQuad™: Participants With 1 or More Injection-Site Adverse Experiences701 of 1,415

164 of 334

0.4 points

-5.5 to 6.4

1,749NCT00326183

Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=194"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=194

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00605865-8d117e32",
        "title": "With Complications vs Without Complications: Factors Considered to Affect the Efficacy of Sertraline: Complication ;Complications is the Patient's Current Experiences With Illnesses, Operations, Injuries and Treatments.",
        "summary": "528 of 637 against 981 of 1128; risk difference -4.1 points, 95% interval -7.7 to -0.6; NCT00605865, Drug Use Investigation of Jzoloft.",
        "record": "/library/comparisons/NCT00605865-8d117e32",
        "nct_id": "NCT00605865",
        "kind": "outcome",
        "participants": 1765,
        "risk_difference": {
          "value": -0.04079545074985802,
          "lower": -0.0770129993696266,
          "upper": -0.006446074987908126
        },
        "group_1": "528 of 637",
        "group_2": "981 of 1,128",
        "difference": "-4.1 points",
        "interval": "-7.7 to -0.6",
        "trial_title": "Drug Use Investigation of Jzoloft."
      },
      {
        "id": "NCT00605865-c25a0018",
        "title": "15 Years and Higher vs Under 15 Years: Factors Considered to Affect the Efficacy of Sertraline: 15 Years and Higher of Age or Not",
        "summary": "1508 of 1762 against 1 of 3; risk difference 52.3 points, 95% interval 6.3 to 79.5; NCT00605865, Drug Use Investigation of Jzoloft.",
        "record": "/library/comparisons/NCT00605865-c25a0018",
        "nct_id": "NCT00605865",
        "kind": "outcome",
        "participants": 1765,
        "risk_difference": {
          "value": 0.5225122966326146,
          "lower": 0.0631840171679276,
          "upper": 0.7948024681500782
        },
        "group_1": "1,508 of 1,762",
        "group_2": "1 of 3",
        "difference": "52.3 points",
        "interval": "6.3 to 79.5",
        "trial_title": "Drug Use Investigation of Jzoloft."
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=195",
  "request_id": "1VawcfiAAGmp-GGz"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?